✦ LIBER ✦

A double-blind comparison of acute buprenorphine with placebo in schizophrenia

✍ Scribed by Nutt, D.J.; Groves, S.

Book ID: 122397355
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 80 KB
Volume: 6
Category: Article
ISSN: 0920-9964
DOI: 10.1016/0920-9964(92)90142-R

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ondansetron. A double blind placebo cont

Ondansetron. A double blind placebo controlled study in acute schizophrenia

✍ McBain, S.L.; Dineen, M.; Weller, M.; Taylor, S.; Cooksey, P.; Williams, P.; Cor 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 106 KB

SM-13496 in patients with acute exacerba

SM-13496 in patients with acute exacerbation of schizophrenia: A two-dose double-blind phase II comparison with placebo

✍ M. Ogasa; T. Kimura; M. Boylan; J. Guarino; M. Nakamura 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 126 KB

A double-blind comparison of risperidone

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

✍ Steven G. Potkin; Georges M. Gharabawi; Andrew J. Greenspan; Ramy Mahmoud; Colet 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 315 KB

Double Blind Comparison of Thiothixene a

Double Blind Comparison of Thiothixene and Trifluoperazine in Acute Schizophrenia

✍ Denber, Herman C.B.; Turns, Danielle 📂 Article 📅 1972 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 667 KB

Sublingual buprenorphine as postoperativ

Sublingual buprenorphine as postoperative analgesic: a double-blind comparison with pethidine

✍ G. Moa; H. Zetterström 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB

Sulpiride in negative schizophrenia: A p

Sulpiride in negative schizophrenia: A placebo-controlled double-blind assessment

✍ S. D. Soni; A. Mallik; A. A. Schiff 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

Twenty-four chronic schizophrenic long-stay hospital patients were identified, who had not received neuroleptic drugs for 8-30 (average 8 months) and met or exceeded a minimum criterion of severity of negative symptoms. They were randomly allocated to either sulpiride 200 mg twice daily or matching